1 / 4

#1060 Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers

#1060 Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers.

gregbryant
Download Presentation

#1060 Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. #1060 Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers High risk salivary cancers are ordinarily treated with surgery and postoperative radiotherapy (PORT). Concurrent chemotherapy with PORT (CRT) has been shown to intensify treatment and improve outcomes in squamous carcinomas of the head and neck. We sought to retrospectively compare outcomes of PORT and CRT in salivary gland carcinomas. • Patients were included if they met basic criteria for entry on RTOG 1008 • Grade 2-3 adenocarcinoma or mucoepidermoid carcinoma, • OR Grade 3 salivary duct, acinic cell or adenoid cystic carcinoma [>30% solid component], • AND • pT3-4 • pN1-3 • OR pT1-2N0 with close [≤1 mm] or positive margins, • AND • age ≥ 18 years • 66 patients meeting the above criteria were included.

  2. Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers RT (n= 39) and CRT (n=27) cohorts had the following differences in presenting characteristics: On binary logistic regression analysis, only N+ was associated with use of concurrent chemotherapy, OR 8.91 (95% CI 2.84 – 27.98, p < 0.001).

  3. Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers p = 0.793 p = 0.001 Figure 1: Disease Free Survival Figure 2: Disease Free Survival, N+ Cohort p = 0.793

  4. Postoperative Chemoradiotherapy in High Risk Salivary Gland Cancers • Conclusion: • In this cohort of high risk salivary cancer eligible for RTOG 1008, post-operative CRT was not associated with improved outcomes over PORT alone. • Node positive patients, especially N2+, are at highest risk for recurrence. This subgroup may benefit from the addition of standard or novel systemic therapies.

More Related